1.14 USD
▼-0.03-2.56%
盘后 1.32 0.00%
2026-09-16
市值
$19.01M
市盈率
—
EPS
-0.47
股息率
—
52 周区间
0.84 – 2.46
成交量
19.37K
Beta
1.53
目标价
7.87
52W 低 0.8452W 高 2.46
价格走势
公司简介
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreat...